(More on compulsory licensing here.) This is a non-exhaustive set of provisions in US statutes that are used to for non-voluntary use of patented inventions. 28 U.S.C. 1498 – Patent and copyright cases (a) Whenever an invention described in and… Continue Reading
Global norms on compulsory licensing Country experiences Compulsory licensing in the United States Statutory authority for compulsory licenses on patents in the United States Compulsory licensing as a remedy to anticompetitive practices Compulsory licensing under the Bayh-Dole Act Compulsory licensing… Continue Reading
KEI has permanent observer status for the World Intellectual Property Organization (WIPO), and has attended every SCCR meeting beginning in 2003, and monitors several other committees. KEI played a key role in the negotiations on the Marrakesh treaty for persons… Continue Reading
You also can search for our most recent work on clustered regularly interspaced short palindromic repeats (CRISPR) technologies using our tags here, or via our general search engine here. KEI Events regarding CRISPR 2019: Expert Workshop at Brocher Foundation- An… Continue Reading
KEI publishes research and commentary in a variety of journals, periodicals, books and other independent publishing platforms. In-house, KEI presents information in blogs, correspondence and reports, as well as in occasional KEI research notes and papers. Timelines (several) Timelines regarding… Continue Reading
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation.
My name is James Love. I work for Knowledge Ecology International, an NGO that focuses on the social aspects to the production, management and control of knowledge goods. I am also a member of the board of directors of the Union for Affordable Cancer Treatment.
The IP Chapter is complex, and in the time allocated, I will discuss five issues.
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).
Today at WIPO, KEI hosted a side event to discuss the ability of countries to deny injunctions in patent infringement cases.
On July 4th, 2017, Andrew Goldman delivered Knowledge Ecology International’s intervention on patents at health at the 26th session of the WIPO Standing Committee on the Law of Patents (SCP).
KEI Statement on Patents and Health
WIPO Standing Committee on the Law of Patents – 26th SessionJuly 4th, 2017
Since the African Group and Development Agenda Group first tabled their proposal on a work program on patents and health in May 2011, much has happened.